Last reviewed · How we verify
ANTI-ANGIN® FORMULA
Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload.
Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload. Used for Angina pectoris (stable and unstable), Prophylaxis of anginal attacks.
At a glance
| Generic name | ANTI-ANGIN® FORMULA |
|---|---|
| Sponsor | Sandoz |
| Drug class | Anti-anginal combination therapy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
The formulation typically contains multiple active ingredients (such as molsidomine or similar nitrate-like compounds) that work synergistically to dilate coronary vessels, improve myocardial oxygen supply, and reduce the frequency and severity of anginal attacks. The combination approach targets both the hemodynamic and metabolic aspects of angina pectoris.
Approved indications
- Angina pectoris (stable and unstable)
- Prophylaxis of anginal attacks
Common side effects
- Headache
- Dizziness
- Hypotension
- Tachycardia
Key clinical trials
- A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat (PHASE3)
- Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANTI-ANGIN® FORMULA CI brief — competitive landscape report
- ANTI-ANGIN® FORMULA updates RSS · CI watch RSS
- Sandoz portfolio CI